Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case.
Case Details
The Complaint alleges that Defendants made false and misleading statements and/or failed to disclose material information regarding the efficacy of simufilam, Cassava’s leading drug candidate for Alzheimer’s Disease. Specifically, the Complaint alleges that Defendants misled investors by expressing confidence in simufilam’s ability to treat Alzheimer’s Disease. The Complaint continues to allege that on November 25, 2024, Cassava announced that simufilam failed to meet its primary and secondary endpoints in a Phase 3 clinical trial.
What’s Next?
A class action lawsuit has already been filed. You may review a copy of the Complaint. You may also contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660. If you suffered a loss in Cassava you have until February 10, 2025, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.
SAVA — Stock Performance
About Bronstein, Gewirtz & Grossman, LLC
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace.”